3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of 3-AP and doxorubicin in
treating patients with metastatic or refractory solid tumors. Drugs used in chemotherapy,
such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop
growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth and may help doxorubicin kill more cancer cells by making them more
sensitive to the drug.